Clinical Trial

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Name: Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT — clinical trial record (NCT06482801)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).

Trial Details

NCT Number	NCT06482801
Lead Sponsor	Second Affiliated Hospital of Guangzhou Medical University
Conditions	Liver Cancer, Antibody
Enrollment	90 participants
Start Date	2024-06-10
Primary Completion	2030-12-30 (estimated)
Study Completion	2035-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-07-01